Editorial 2: Efficacy and Safety Outcomes in Clinical Trials of Proprotein Convertase Subtilisin-Kexin (PCSK) Type 9 Inhibitors in Coronary Artery Disease

Publisher: Nova Science Publishers, Inc.

ISSN: 1556-4002

Source: World Heart Journal, Vol., Iss., 2017-01, pp. : 15-18

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content